Sodium-Glucose Cotransporter-2 Inhibitors and Lower-Extremity Amputation

Type-2 diabetes mellitus (T2DM) is a risk factor for cardiovascular and renal disease, and the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors was shown to have favorable effects on relevant biomarkers and to reduce the risk of serious cardiovascular and renal complications.1–4 SGLT2 inhibi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of cardiology 2023-08, Vol.201, p.388-389
1. Verfasser:	Aizawa, Yoshifusa
Format:	Artikel
Sprache:	eng
Schlagworte:	Amputation Amputation, Surgical Antidiabetics Biomarkers Cardiovascular disease Cardiovascular diseases Clinical trials Complications Confidence intervals Diabetes Diabetes mellitus Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Glucagon Glucagon-like peptide 1 Glucose Health risks Humans Hypoglycemic Agents Inhibitors Leg Metformin Observational studies Placebos Risk factors Sodium Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Sulfonylurea Thiazolidinediones
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!